Exact Sciences Corp
NASDAQ:EXAS

Watchlist Manager
Exact Sciences Corp Logo
Exact Sciences Corp
NASDAQ:EXAS
Watchlist
Price: 50.73 USD 1.14% Market Closed
Market Cap: 9.4B USD
Have any thoughts about
Exact Sciences Corp?
Write Note

Wall Street
Price Targets

EXAS Price Targets Summary
Exact Sciences Corp

Wall Street analysts forecast EXAS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EXAS is 81.05 USD with a low forecast of 61.61 USD and a high forecast of 105 USD.

Lowest
Price Target
61.61 USD
21% Upside
Average
Price Target
81.05 USD
60% Upside
Highest
Price Target
105 USD
107% Upside

EXAS Last Price Targets
Exact Sciences Corp

The latest public price target was made on Nov 6, 2024 by Catherine Schulte from Robert W. Baird , who expects EXAS stock to rise by 32% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Catherine Schulte
Robert W. Baird
67 USD
Upside 32%
1 week ago
Nov 6, 2024
Exact Sciences (EXAS) PT Lowered to $67 at Baird
StreetInsider
Mark Massaro
BTIG
65 USD
Upside 28%
1 week ago
Nov 6, 2024
Exact Sciences (EXAS) PT Lowered to $65 at BTIG
StreetInsider
Kyle Mikson
Canaccord Genuity
95 USD
Upside 87%
2 weeks ago
Oct 29, 2024
Exact Sciences (EXAS) PT Raised to $95 at Canaccord Genuity
StreetInsider
Vijay Kumar
Evercore ISI
80 USD
Upside 58%
1 month ago
Oct 1, 2024
Exact Sciences price target raised to $80 from $72 at Evercore ISI
TheFly
Mark Massaro
BTIG
82 USD
Upside 62%
1 month ago
Sep 16, 2024
Exact Sciences price target raised to $82 from $70 at BTIG
TheFly
Patrick Donnelly
Citigroup
80 USD
Upside 58%
1 month ago
Sep 16, 2024
Citi Reiterates Buy Rating on Exact Sciences (EXAS)
StreetInsider
Kyle Mikson
Canaccord Genuity
75 USD
Upside 48%
2 months ago
Sep 13, 2024
Canaccord Genuity Reiterates Buy Rating on Exact Sciences (EXAS)
StreetInsider
David Westenberg
Piper Sandler
85 USD
Upside 68%
2 months ago
Sep 12, 2024
Exact Sciences (EXAS) PT Raised to $85 at Piper Sandler
StreetInsider
David Westenberg
Piper Sandler
80 USD
Upside 58%
3 months ago
Jul 19, 2024
Piper Sandler Reiterates Overweight Rating on Exact Sciences (EXAS)
StreetInsider
Mark Massaro
BTIG
70 USD
Upside 38%
4 months ago
Jun 26, 2024
Exact Sciences price target lowered to $70 from $80 at BTIG
TheFly
Sung Ji Nam
Scotiabank
70 USD
Upside 38%
4 months ago
Jun 26, 2024
Exact Sciences initiated with an Outperform at Scotiabank
TheFly
Tycho Peterson
Jefferies
75 USD
Upside 48%
5 months ago
Jun 3, 2024
Exact Sciences assumed with a Buy at Jefferies
TheFly
Kyle Mikson
Canaccord Genuity
85 USD
Upside 68%
6 months ago
May 9, 2024
Exact Sciences price target lowered to $85 from $90 at Canaccord
TheFly
Patrick Donnelly
Citigroup
130 USD
Upside 156%
1 year ago
Jun 22, 2023
Exact Sciences Set To Dominate Emerging Precision Oncology Market: Analyst Applauds $18B Potential Market
Benzinga
Show More Price Targets
Show Less Price Targets
Catherine Schulte
Robert W. Baird
Price Target 67 USD
Upside/Downside 32%
View Source
Mark Massaro
BTIG
Price Target 65 USD
Upside/Downside 28%
View Source
Kyle Mikson
Canaccord Genuity
Price Target 95 USD
Upside/Downside 87%
View Source
Vijay Kumar
Evercore ISI
Price Target 80 USD
Upside/Downside 58%
View Source
Mark Massaro
BTIG
Price Target 82 USD
Upside/Downside 62%
View Source
Patrick Donnelly
Citigroup
Price Target 80 USD
Upside/Downside 58%
View Source
Kyle Mikson
Canaccord Genuity
Price Target 75 USD
Upside/Downside 48%
View Source
David Westenberg
Piper Sandler
Price Target 85 USD
Upside/Downside 68%
View Source
David Westenberg
Piper Sandler
Price Target 80 USD
Upside/Downside 58%
View Source
Mark Massaro
BTIG
Price Target 70 USD
Upside/Downside 38%
View Source
Sung Ji Nam
Scotiabank
Price Target 70 USD
Upside/Downside 38%
View Source
Tycho Peterson
Jefferies
Price Target 75 USD
Upside/Downside 48%
View Source
Kyle Mikson
Canaccord Genuity
Price Target 85 USD
Upside/Downside 68%
View Source
Patrick Donnelly
Citigroup
Price Target 130 USD
Upside/Downside 156%
View Source
Show More Price Targets
Show Less Price Targets
Exact Sciences Corp Competitors:
Price Targets
302440
SK Bioscience Co Ltd
11% Upside
MRUS
Merus NV
78% Upside
SNDX
Syndax Pharmaceuticals Inc
117% Upside
MRNA
Moderna Inc
135% Upside
MREO
Mereo Biopharma Group PLC
81% Upside
PTGX
Protagonist Therapeutics Inc
26% Upside
CGON
CG Oncology Inc
96% Upside
ANIK
Anika Therapeutics Inc
107% Upside

Revenue
Forecast

Revenue Estimate
Exact Sciences Corp

For the last 8 years the compound annual growth rate for Exact Sciences Corp's revenue is 68%. The projected CAGR for the next 3 years is 12%.

68%
Past Growth
12%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Exact Sciences Corp

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Exact Sciences Corp

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EXAS's stock price target?
Price Target
81.05 USD

According to Wall Street analysts, the average 1-year price target for EXAS is 81.05 USD with a low forecast of 61.61 USD and a high forecast of 105 USD.

What is Exact Sciences Corp's Revenue forecast?
Projected CAGR
12%

For the last 8 years the compound annual growth rate for Exact Sciences Corp's revenue is 68%. The projected CAGR for the next 3 years is 12%.

Back to Top